Abstract
The pharmaceutical market in the Middle East is valued at more than $9.4b and is expected to grow over at a rate of 10% annually. Although there continues to be unrest in the region and around the world, both economically and politically, the Middle East has seen a shift and the pharmaceutical market is becoming more attractive. These countries are traditionally high importers of originator brands and branded generic drugs. Although originator drugs have previously held most of the market, new policies that favor generics are being implemented in the region. The pharmaceutical market ranges quite a bit within the various countries in the Middle East, Bahrain remains the smallest market with Saudi Arabia being the largest due to a growing population and new westernized lifestyle. Policy makers in the region should continue to encourage new players by continuing to propose new policies that allow for continued growth
Get full access to this article
View all access options for this article.